Gary Sender - Nabriva Therapeutics Consultant
Executive
Mr. Gary L. Sender is a Chief Financial Officer of the Company. Mr. Sender has served as our chief financial officer since May 2016. Prior to joining our company, he served as chief financial officer and executive vice president at Synergy Pharmaceuticals from 2015 to 2016. From 2009 until 2015, Mr. Sender served as senior vice president, Finance at Shire plc., supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. He was responsible for financial management and support of all commercial areas of Shires Specialty Pharmaceutical and Rare Disease businesses, with an emphasis on resource allocation, financial forecasting, business cases and mergers and acquisitions. Prior to joining Shire, Mr. Sender was the founding CFO of Tengion, Inc. Mr. Sender also spent 15 years in a number of leadership roles within Merck since 2016.
| Age | 61 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Phone | 353 1 649 2000 |
| Web | https://www.nabriva.com |
Nabriva Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.652) % which means that it has lost $0.652 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6853) %, meaning that it created substantial loss on money invested by shareholders. Nabriva Therapeutics' management efficiency ratios could be used to measure how well Nabriva Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Nabriva Therapeutics AG currently holds 5.22 M in liabilities with Debt to Equity (D/E) ratio of 0.21, which may suggest the company is not taking enough advantage from borrowing. Nabriva Therapeutics has a current ratio of 2.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Nabriva Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 9 records | EXECUTIVE Age | ||
| Rick McElheny | Clearside Biomedical | N/A | |
| Mark CPA | Evoke Pharma | 48 | |
| MD MBA | Clearside Biomedical | 59 | |
| Leslie JD | Clearside Biomedical | 56 | |
| Leslie Zacks | Clearside Biomedical | 55 | |
| FRCOphth FRCS | Clearside Biomedical | N/A | |
| Charles Deignan | Clearside Biomedical | 61 | |
| DMD MD | Evoke Pharma | 76 | |
| Marilyn Carlson | Evoke Pharma | 76 | |
Management Performance
| Return On Equity | -2.69 | |||
| Return On Asset | -0.65 |
Nabriva Therapeutics Leadership Team
Elected by the shareholders, the Nabriva Therapeutics' board of directors comprises two types of representatives: Nabriva Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nabriva. The board's role is to monitor Nabriva Therapeutics' management team and ensure that shareholders' interests are well served. Nabriva Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nabriva Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gary Sender, Consultant | ||
| BA Esq, G Sec | ||
| Daniel Dolan, Chief Officer | ||
| Steven D, Chief Devel. Officer and Member of Management Board | ||
| Jodi VanDerveer, VP HR | ||
| Werner Heilmayer, VP IP | ||
| Colin MD, CEO and Member of Management Board | ||
| Theodore Schroeder, CEO Director | ||
| MBA MD, Chief Officer |
Nabriva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nabriva Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.69 | |||
| Return On Asset | -0.65 | |||
| Profit Margin | (1.48) % | |||
| Operating Margin | (1.29) % | |||
| Current Valuation | 3.29 M | |||
| Shares Outstanding | 3.2 M | |||
| Shares Owned By Insiders | 0.96 % | |||
| Shares Owned By Institutions | 8.77 % | |||
| Number Of Shares Shorted | 44.59 K | |||
| Price To Earning | (0.48) X |
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Nabriva Stock
If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |